Computer-tailored drug dosing aims to tame Crohn's in kids
NCT ID NCT04974099
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tested whether a computer program that customizes infliximab doses based on blood tests can help children and young adults with Crohn's disease reach better drug levels than standard dosing. Only 6 participants were enrolled before the study was stopped early. The goal was to see if personalized dosing is feasible and safe, not to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- infliximab
- What this could lead to
- If successful, this could show that personalized dosing helps more patients reach optimal drug levels, potentially improving disease control.
- What could go wrong
- This was a small, terminated early study with only 6 participants, so results are very limited and may not apply broadly. The approach may not prove better than standard dosing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
6 people
The number who actually took part.
- Started
-
Oct 2021
- Finished
-
Aug 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
6 to 22 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Written informed consent form from the patient (≥18 years old) or from parent/legal guardian if patient is \<18 years old. 2. Written informed assent form from patient ≥11 years old. 3. Age criteria: ≥6 years to ≤22 years of age. 4. Diagnosis of Crohn's Disease 5. Starting infliximab (or biosimilar) 6. Anti-TNF naïve (never received infliximab, adalimumab, golimumab, certolizumab or anti-TNF biosimilar) 7. Fecal calprotectin \>250 µg/g or fecal lactoferrin \>10 µg/g (up to 6 weeks prior to starting infliximab) or endoscopic evidence of active Crohn's disease (up to 90 days prior to starting infliximab) 8. wPCDAI \>12.5 (up to 6 weeks) prior to the first infliximab infusion 9. Negative urine pregnancy test for ALL female subjects 10. Negative TB (tuberculosis) blood test Exclusion Criteria: 1. Diagnosis of ulcerative colitis or inflammatory bowel disease-unspecified 2. Prior treatment with infliximab, adalimumab, certolizumab or golimumab (or anti-TNF biosimilar) 3. Active or prior evidence in past 12 months of internal (abdominal/pelvic) penetrating fistula(e) 4. Active intestinal stricture (luminal narrowing with pre-stenotic dilation \>3mm), intra-abdominal abscess or perianal abscess 5. Active Clostridium difficile infection or other known bacterial/viral gastroenteritis in last two weeks 6. Current ileostomy, colostomy, ileoanal pouch, and/or previous extensive small bowel resection leading to short bowel syndrome 7. History of autoimmune disease (including autoimmune hepatitis, primary sclerosing cholangitis, thyroiditis, psoriasis or juvenile idiopathic arthritis) 8. Treatment with another investigational drug within four weeks. 9. Treatment with intravenous antibiotics within four weeks. 10. Planned continuation of 6-mercaptopurine or azathioprine (Imuran) during study. 11. Planned continuation of methotrexate during study. 12. Treatment with intravenous corticosteroids within two weeks. 13. Currently pregnant, breast feeding or plans in next 12 months to become pregnant 14. Inability or failure to provide informed assent/consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Crohn disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cincinnati Children's Hospital
Cincinnati, Ohio, 45229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mini-Guts in a dish: scientists probe why IBD tissue struggles to heal
- Can immune aging blood tests predict which older IBD patients thrive on advanced therapies?
- Can a liquid diet calm Crohn's in kids?
- Which IBD therapy works best for kids? researchers compare two approaches
- Can trained peer mentors ease the mental toll of IBD?
- Can a new pill tame inflammatory bowel disease?